2014: Dulaglutide (Trulicity) is approved by the FDA, and is recognized as the first type 2 diabetes drug to reduce the risk of major adverse cardiovascular events (MACE)
In the key secondary endpoint for body weight, 12 mg and 36 mg doses led to statistically significant reductions: A1C reduction: 1.2% (3 mg), 1.5% (12 mg), 1.5% (36 mg), 0.4% (placebo) Percent weight reduction: 4.5% (3 mg), 5.8% (12 mg), 7.6% (36 mg), 1.7% (placebo) Weight reduction: 4.2 kg (9.3 lbs
BPC-157 works by enhancing the bodys natural repair responseit doesnt choose an injury but rather amplifies healing processes wherever damage is present
The Medicines and Healthcare products Regulatory Agency (MHRA) has warned healthcare professionals to be aware of the potential risk of pulmonary aspiration in patients using glucagon-like peptide-1 (GLP-1) or dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists (GLP-1 RAs), who undergo surgery or procedures with general anaesthesia or deep sedation
Research has shown that a 4mm needle is sufficient to reach this layer in the vast majority of adults, regardless of their Body Mass Index (BMI)
References 1 DobricADe LucaSNSpencerSJBozinovskiSSalingMMMcDonaldCFet al
